Intracerebroventricular Administration of Neuropeptide Y Induces Hepatic Insulin Resistance via Sympathetic Innervation
- Anita M. van den Hoek1,
- Caroline van Heijningen2,
- Janny P. Schröder-van der Elst3,
- D. Margriet Ouwens4,
- Louis M. Havekes1356,
- Johannes A. Romijn3,
- Andries Kalsbeek2 and
- Hanno Pijl3
- 1TNO-Quality of Life, Gaubius Laboratory, Leiden, the Netherlands
- 2Netherlands Institute for Neuroscience, Amsterdam, the Netherlands
- 3Department of Endocrinology and Metabolic Diseases, Leiden University Medical Center, Leiden, the Netherlands
- 4Department of Molecular Cell Biology, Leiden University Medical Center, Leiden, the Netherlands
- 5Department of Internal Medicine, Leiden University Medical Center, Leiden, the Netherlands
- 6Department of Cardiology, Leiden University Medical Center, Leiden, the Netherlands
- Corresponding author: Anita van den Hoek, a.vandenhoek{at}tno.nl
Abstract
OBJECTIVE—We recently showed that intracerebroventricular infusion of neuropeptide Y (NPY) hampers inhibition of endogenous glucose production (EGP) by insulin in mice. The downstream mechanisms responsible for these effects of NPY remain to be elucidated. Therefore, the aim of this study was to establish whether intracerebroventricular NPY administration modulates the suppressive action of insulin on EGP via hepatic sympathetic or parasympathetic innervation.
RESEARCH DESIGN AND METHODS—The effects of a continuous intracerebroventricular infusion of NPY on glucose turnover were determined in rats during a hyperinsulinemic-euglycemic clamp. Either rats were sham operated, or the liver was sympathetically (hepatic sympathectomy) or parasympathetically (hepatic parasympathectomy) denervated.
RESULTS—Sympathectomy or parasympathectomy did not affect the capacity of insulin to suppress EGP in intracerebroventricular vehicle–infused animals (50 ± 8 vs. 49 ± 6 vs. 55 ± 6%, in hepatic sympathectomy vs. hepatic parasympathectomy vs. sham, respectively). Intracerebroventricular infusion of NPY significantly hampered the suppression of EGP by insulin in sham-denervated animals (29 ± 9 vs. 55 ± 6% for NPY/sham vs. vehicle/sham, respectively, P = 0.038). Selective sympathetic denervation of the liver completely blocked the effect of intracerebroventricular NPY administration on insulin action to suppress EGP (NPY/hepatic sympathectomy, 57 ± 7%), whereas selective parasympathetic denervation had no effect (NPY/hepatic parasympathectomy, 29 ± 7%).
CONCLUSIONS—Intracerebroventricular administration of NPY acutely induces insulin resistance of EGP via activation of sympathetic output to the liver.
Footnotes
-
Published ahead of print at http://diabetes.diabetesjournals.org on 10 June 2008.
A.K. and H.P. contributed equally to this work.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
-
- Accepted May 30, 2008.
- Received November 27, 2007.
- DIABETES
